for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aurinia Pharmaceuticals Inc

AUP.TO

Latest Trade

5.44CAD

Change

-0.14(-2.51%)

Volume

58,023

Today's Range

5.27

 - 

5.79

52 Week Range

4.70

 - 

10.47

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5.58
Open
5.60
Volume
58,023
3M AVG Volume
0.72
Today's High
5.79
Today's Low
5.27
52 Week High
10.47
52 Week Low
4.70
Shares Out (MIL)
94.29
Market Cap (MIL)
509.28
Forward P/E
-6.12
Dividend (Yield %)
--

Latest Developments

More

Aurinia Reports Q2 2019 Results

Aurinia Pharmaceuticals Inc Qtrly Loss Per Share $0.14

Iljin SNT Co Says Now "Seriously Considering" Whether To Nominate New Directors To Aurinia's Board

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Industry

Biotechnology & Drugs

Contact Info

1203-4464 Markham St

+1.250.7084272

https://www.auriniapharma.com

Executive Leadership

George M. Milne

Executive Chairman of the Board

Peter S. Greenleaf

Chief Executive Officer, Director

Dennis Bourgeault

Chief Financial Officer, Corporate Secretary

Michael R. Martin

Chief Operating Officer

Neil Solomons

Chief Marketing Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.660

2017

-0.920

2018

-0.760

2019(E)

-0.673
Price To Earnings (TTM)
--
Price To Sales (TTM)
833.56
Price To Book (MRQ)
2.99
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.33
LT Debt To Equity (MRQ)
0.23
Return on Investment (TTM)
-39.95
Return on Equity (TTM)
-38.40

Latest News

Latest News

BRIEF-Aurinia Pharmaceuticals Reports Qtrly Loss Per Share ‍of $0.04​

* AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BRIEF-Aurinia Pharmaceuticals Files For Mixed Shelf Of Up To $250 Mln

* AURINIA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION – SEC FILING Source text: [http://bit.ly/2CTvkK1] Further company coverage:

BRIEF-Aurinia Pharmaceuticals Added To The Nasdaq Biotech Index

* AURINIA PHARMACEUTICALS ADDED TO THE NASDAQ BIOTECH INDEX Source text for Eikon: Further company coverage:

BRIEF-Aurinia reports Q3 loss per share $0.16

* Aurinia reports third quarter 2017 financial results and provides operational highlights

BRIEF-Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing

* Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing

BRIEF-Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise

* Aurinia Pharmaceuticals Inc - plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease

BRIEF-Aurinia Pharmaceuticals reports Q2 loss per share $‍0.03​

* Aurinia reports second quarter 2017 financial results, and provides operational highlights

BRIEF-Aurinia Pharmaceuticals resolves temporary non-compliance with Nasdaq's audit committee composition rule

* Aurinia resolves temporary non-compliance with Nasdaq's audit committee composition rule Source text for Eikon: Further company coverage:

BRIEF-Aurinia Pharma presents voclosporin remission data

* Voclosporin remission data from the phase IIB aura-LV study highlighted at eular 2017

BRIEF-Aurinia doses first patient in AURORA phase 3 clinical trial of voclosporin in lupus nephritis

* Aurinia doses first patient in AURORA phase 3 clinical trial of voclosporin in lupus nephritis

BRIEF-George Milne joins Aurinia’s board of directors

* Pharma industry veteran Dr. George Milne joins Aurinia’s board of directors Source text for Eikon: Further company coverage:

BRIEF-Aurinia Pharmaceuticals releases additional 48-week data from AURA-LV study

* Aurinia releases additional 48-week data from the AURA-LV study during late-breaking session at the National Kidney Foundation 2017 spring clinical meetings

BRIEF-Aurinia completes licensing deal with Merck Animal Health

* Aurinia completes licensing deal with Merck Animal Health for its nanomicellar formulation of voclosporin for the treatment of canine dry eye syndrome

BRIEF-Aurinia announces development plans for Voclosporin in Europe and Japan

* Aurinia announces development plans for Voclosporin in Europe and Japan

BRIEF-Aurinia announces public offering of common shares

* Aurinia Pharmaceuticals-to use net proceeds of offering for research, development activities, phase 3 clinical trial activities for lupus nephritis Source text for Eikon: Further company coverage:

BRIEF-Aurinia Q4 loss per share $0.21

* Aurinia reports fourth quarter and full year 2016 financial results and recent operational highlights

Aurinia's lupus drug shows no new safety concerns

Aurinia Pharmaceuticals Inc said there were no further deaths in patients given its experimental lupus drug in a mid-stage study, allaying safety concerns as the drug developer prepares to start a pivotal study later this year.

BRIEF-Aurinia Pharmaceuticals announces Voclosporin results from Japanese Phase I study

* Aurinia Pharmaceuticals Inc announces results from Japanese Phase I ethnic bridging study for Voclosporin

BRIEF-Aurinia Pharmaceuticals announces appoints Richard Glickman as new CEO

* AURINIA ANNOUNCES APPOINTMENT OF COMPANY FOUNDER, DR. RICHARD M. GLICKMAN, AS ITS NEW CHIEF EXECUTIVE OFFICER

BRIEF-Aurinia selects Worldwide Clinical Trials as its CRO for Phase 3 lupus nephritis trial

* Aurinia selects Worldwide Clinical Trials as its CRO for Phase 3 lupus nephritis trial

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up